We could not find any results for:
Make sure your spelling is correct or try broadening your search.
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specifi... CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes. Show more
ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
-CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.34 | 0.715036803365 | 47.55 | 48.44 | 45.51 | 2108494 | 47.03386276 | CS |
4 | -0.04 | -0.083455038598 | 47.93 | 59.0693 | 45.51 | 1867040 | 49.45965403 | CS |
12 | 0.17 | 0.356244761106 | 47.72 | 59.0693 | 43.42 | 1298224 | 48.20554663 | CS |
26 | -6.8 | -12.4337173158 | 54.69 | 67.88 | 43.42 | 1276957 | 51.92750118 | CS |
52 | -20.8 | -30.2809724851 | 68.69 | 91.1 | 43.42 | 1669002 | 61.189556 | CS |
156 | -34.53 | -41.895171075 | 82.42 | 91.1 | 37.55 | 1495861 | 60.20017799 | CS |
260 | -11.55 | -19.431359354 | 59.44 | 220.21 | 32 | 1424877 | 79.18714065 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions